WSTWest Pharmaceutical Services

$366.17+44% 1Y

Is the business good?

Mixed

The checks split: 7 of 9 health tests passed and earnings fully cash-backed (1.2×), but margins compressing.

2 good, 1 to watch, 1 neutral
Fundamental health (F-score)7 / 9SEC EDGAR · Dec 31, 2025

High fundamental quality. Nine pass/fail tests of year-over-year health from the filings.

Profits arrive as cash1.23×derived · Jun 30, 2026

Operating profit is fully backed by cash. Conversion is worsening vs a year ago.

Margin direction, 3 years−2.4 pts

Positive operating leverage, operating profit is growing faster than sales, so margins widen as the business scales.

Where ROE comes from13% ROA

Margin-driven, fat margins on slower asset turns. ROE 17% = margin × turnover × leverage.

Unless marked, from derived.

Against the whole market›

Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.

FCF conversionbehind 73% of the market
Leverage (Debt/EBITDA)top 7% of the market

Where this answer is blind. The F-score rewards improvement, so an already-elite company can score mid-pack.

How good a business is WST?

West Pharmaceutical Services earns 19% on the capital it employs against a 9.0% cost of capital, so the business is worth more the bigger it gets.

19%

Return on invested capital · cost of capital 9.0% · 10 points above what the capital costs: growth creates value

Operating margin
20%

Operating margin · Medical Instruments & Supplies median 6.6% · 12 months to Q2 2026

Cash conversion
1.23×

Cash conversion · 1.47× a year ago · operating cash flow covers the operating profit after tax

Share count, year on year
−1.7%

Share count, year on year · bought back, each share owns more of the company

Operating margin by fiscal year
YearOperating margin
FY202019%
FY202127%
FY202225%
FY202323%
FY202420%
FY202519%
Details›
Gross margin12 months to Q2 2026
37%
Operating margin12 months to Q2 2026
20%
Net margin12 months to Q2 2026
17%
Free cash flow margin
13%
R&D as % of revenue
2.2%
Revenue, trailing twelve months
$3.33B
Free cash flow, trailing twelve months
$437M
Net income, trailing twelve months
$565M
Return on invested capitaloperating profit after tax ÷ debt + equity − cash
19%

Margins, capital and share counts from the statements as filed with the SEC; cash conversion is operating cash flow over operating profit after tax.

On our screens:Stocks with no debt